A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia

Authors: Shi Yan, Hu Zhou, Ruibin Huang, Fang Wang, Heng Mei, Lie Lin, Jingming Guo, Xin Zhou, Zhenyu Li, Yaorong Liu, Sichen Li, Wei Zhou, Yu Hou, Ming Hou

Published: 2024-03-28

DOI: HTTPS://DOI.ORG/10.1002/ajh.27303

Keywords: No keywords found.

Abstract:
No abstract found.

Source: